TrialThoracic cancer2025

Efficacy and Safety of Afatinib Plus Bevacizumab as First-Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor (EGFR) Mutations: A Multicenter, Phase II Trial.

Huiyang Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.